"description","instanceType","id","uuid:ID","rationale","name","label"
"The main design for the study","StudyDesign","StudyDesign_1","c8d9e12d-f442-4ea5-a769-2e5f70dea068","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1",""
